Acorah Software Products - Accounts Production 16.6.950 false true 31 March 2024 16 March 2023 false 1 April 2024 31 March 2025 31 March 2025 SC762525 Miss Sehar Shahid Mr Usmaan Shahid iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure SC762525 2024-03-31 SC762525 2025-03-31 SC762525 2024-04-01 2025-03-31 SC762525 frs-core:CurrentFinancialInstruments 2025-03-31 SC762525 frs-core:Non-currentFinancialInstruments 2025-03-31 SC762525 frs-core:ComputerEquipment 2025-03-31 SC762525 frs-core:ComputerEquipment 2024-04-01 2025-03-31 SC762525 frs-core:ComputerEquipment 2024-03-31 SC762525 frs-core:DevelopmentCostsCapitalisedDevelopmentExpenditure 2024-04-01 2025-03-31 SC762525 frs-core:FurnitureFittings 2025-03-31 SC762525 frs-core:FurnitureFittings 2024-04-01 2025-03-31 SC762525 frs-core:FurnitureFittings 2024-03-31 SC762525 frs-core:OtherResidualIntangibleAssets 2025-03-31 SC762525 frs-core:OtherResidualIntangibleAssets 2024-04-01 2025-03-31 SC762525 frs-core:OtherResidualIntangibleAssets 2024-03-31 SC762525 frs-core:ShareCapital 2025-03-31 SC762525 frs-core:RetainedEarningsAccumulatedLosses 2025-03-31 SC762525 frs-bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 SC762525 frs-bus:FilletedAccounts 2024-04-01 2025-03-31 SC762525 frs-bus:SmallEntities 2024-04-01 2025-03-31 SC762525 frs-bus:AuditExempt-NoAccountantsReport 2024-04-01 2025-03-31 SC762525 frs-bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 SC762525 frs-bus:Director1 2024-04-01 2025-03-31 SC762525 frs-bus:Director2 2024-04-01 2025-03-31 SC762525 frs-countries:Scotland 2024-04-01 2025-03-31 SC762525 2023-03-15 SC762525 2024-03-31 SC762525 2023-03-16 2024-03-31 SC762525 frs-core:CurrentFinancialInstruments 2024-03-31 SC762525 frs-core:Non-currentFinancialInstruments 2024-03-31 SC762525 frs-core:ShareCapital 2024-03-31 SC762525 frs-core:RetainedEarningsAccumulatedLosses 2024-03-31
Registered number: SC762525
Next Gen Pharma Ltd
Unaudited Financial Statements
For The Year Ended 31 March 2025
TaxAssist Accountants
Next Gen Pharma Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—4

Page 1
Next Gen Pharma Ltd
Balance Sheet
As At 31 March 2025
Balance Sheet
Registered number: SC762525

| 31 March 2025 | 31 March 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Intangible Assets | 4 |  | 22,020 |  | 25,906
Tangible Assets | 5 |  | 11,517 |  | 14,199
|  |  | 33,537 |  | 40,105
CURRENT ASSETS
Debtors | 6 | 6,368 |  | 6,605 |
Cash at bank and in hand |  | 5,120 |  | 19,759 |
|  | 11,488 |  | 26,364 |
Creditors: Amounts Falling Due Within One Year | 7 | (214,388 ) |  | (115,976 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | (202,900 ) |  | (89,612 )
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | (169,363 ) |  | (49,507 )
Creditors: Amounts Falling Due After More Than One Year | 8 |  | (28,072 ) |  | (38,158 )
NET LIABILITIES |  |  | (197,435 ) |  | (87,665 )
CAPITAL AND RESERVES
Called up share capital | 9 |  | 2 |  | 1
Profit and Loss Account |  |  | (197,437 ) |  | (87,666 )
SHAREHOLDERS' FUNDS |  |  | (197,435) |  | (87,665)

Page 1
Page 2
Next Gen Pharma Ltd
Balance Sheet (continued)
As At 31 March 2025
For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Miss Sehar Shahid Director
13/11/2025

The notes on pages 3 to 4 form part of these financial statements.
Page 2
Page 3
Next Gen Pharma Ltd
Notes to the Financial Statements
For The Year Ended 31 March 2025
Notes to the Financial Statements
1. General Information
Next Gen Pharma Ltd is a private company, limited by shares, incorporated in Scotland, registered number SC762525 . The registered office is Studio 5 Sir James Clark Building, Abbey Mill Business Centre, Paisley, PA1 1TJ.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3. Intangible Fixed Assets and Amortisation - Other Intangible
Other intangible assets are .... It is amortised to the profit and loss account over its estimated economic life of .... years.
2.4. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures & Fittings | RB 20%
Computer Equipment | RB 33.33%

3. Average Number of Employees
Average number of employees, including directors, during the year was: 1 (2024: 1)
1 1
4. Intangible Assets

| Other
--- | ---
| £
Cost
As at 1 April 2024 | 30,478
As at 31 March 2025 | 30,478
Amortisation
As at 1 April 2024 | 4,572
Provided during the period | 3,886
As at 31 March 2025 | 8,458
Net Book Value
As at 31 March 2025 | 22,020
As at 1 April 2024 | 25,906

Page 3
Page 4
Next Gen Pharma Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 March 2025
5. Tangible Assets

| Fixtures & Fittings | Computer Equipment | Total
--- | --- | --- | ---
| £ | £ | £
Cost
As at 1 April 2024 | 15,367 | 2,857 | 18,224
Additions | 113 | 483 | 596
As at 31 March 2025 | 15,480 | 3,340 | 18,820
Depreciation
As at 1 April 2024 | 3,073 | 952 | 4,025
Provided during the period | 2,482 | 796 | 3,278
As at 31 March 2025 | 5,555 | 1,748 | 7,303
Net Book Value
As at 31 March 2025 | 9,925 | 1,592 | 11,517
As at 1 April 2024 | 12,294 | 1,905 | 14,199

6. Debtors

| 31 March 2025 |  | 31 March 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Other debtors | 6,368 |  | 6,605

7. Creditors: Amounts Falling Due Within One Year

| 31 March 2025 |  | 31 March 2024
--- | --- | --- | ---
| £ |  | £
Trade creditors | 4,214 |  | 4,933
Bank loans and overdrafts | 10,087 |  | 9,907
Amounts owed to participating interests | 28,240 |  | 28,490
Other creditors | 171,847 |  | 72,633
Taxation and social security | - |  | 13
| 214,388 |  | 115,976

8. Creditors: Amounts Falling Due After More Than One Year

| 31 March 2025 |  | 31 March 2024
--- | --- | --- | ---
| £ |  | £
Bank loans | 28,072 |  | 38,158

9. Share Capital

| 31 March 2025 |  | 31 March 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 2 |  | 1

Page 4